Humedix Co., Ltd. Logo

Humedix Co., Ltd.

200670.KQ

(0.0)
Stock Price

26.450,00 KRW

13.61% ROA

15.66% ROE

10.97x PER

Market Cap.

360.375.345.400,00 KRW

1.11% DER

1.72% Yield

19.32% NPM

Humedix Co., Ltd. Stock Analysis

Humedix Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Humedix Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Humedix Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Humedix Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Humedix Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Humedix Co., Ltd. Revenue
Year Revenue Growth
2015 42.133.250
2016 47.133.616.792 99.91%
2017 54.727.015.692 13.88%
2018 64.831.668.744 15.59%
2019 78.618.778.772 17.54%
2020 98.480.868.087 20.17%
2021 110.992.354.033 11.27%
2022 123.172.789.865 9.89%
2023 152.273.808.567 19.11%
2024 183.446.329.864 16.99%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Humedix Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 3.323.376
2016 4.685.058.086 99.93%
2017 4.632.611.600 -1.13%
2018 4.964.130.437 6.68%
2019 5.729.022.000 13.35%
2020 7.502.582.133 23.64%
2021 9.097.441.000 17.53%
2022 9.721.364.000 6.42%
2023 9.770.243.958 0.5%
2024 13.816.368.000 29.29%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Humedix Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 2.476.369
2016 2.803.515 11.67%
2017 4.509.644 37.83%
2018 5.531.554 18.47%
2019 7.699.881 28.16%
2020 1.903.767.920 99.6%
2021 2.454.094.810 22.42%
2022 2.533.084.740 3.12%
2023 2.922.486.800 13.32%
2024 38.420.549.600 92.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Humedix Co., Ltd. EBITDA
Year EBITDA Growth
2015 15.551.962
2016 15.074.630.250 99.9%
2017 16.034.262.350 5.98%
2018 17.798.777.830 9.91%
2019 21.814.929.460 18.41%
2020 26.954.554.500 19.07%
2021 27.623.479.780 2.42%
2022 36.672.088.590 24.67%
2023 48.297.389.130 24.07%
2024 63.802.654.840 24.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Humedix Co., Ltd. Gross Profit
Year Gross Profit Growth
2015 21.668.993
2016 22.260.678.713 99.9%
2017 24.133.326.153 7.76%
2018 25.090.167.859 3.81%
2019 31.715.551.523 20.89%
2020 38.034.442.832 16.61%
2021 42.064.078.189 9.58%
2022 52.988.549.166 20.62%
2023 68.044.790.267 22.13%
2024 89.385.132.444 23.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Humedix Co., Ltd. Net Profit
Year Net Profit Growth
2015 11.622.597
2016 10.274.737.728 99.89%
2017 11.940.469.309 13.95%
2018 9.207.790.760 -29.68%
2019 10.420.174.416 11.63%
2020 15.084.078.590 30.92%
2021 9.064.623.500 -66.41%
2022 21.086.065.770 57.01%
2023 24.820.704.790 15.05%
2024 47.431.451.400 47.67%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Humedix Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 1.245
2016 1.059 -17.56%
2017 1.230 13.83%
2018 963 -27.62%
2019 1.094 11.89%
2020 1.587 31.13%
2021 964 -64.8%
2022 2.274 57.63%
2023 2.512 9.51%
2024 4.572 45.06%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Humedix Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2015 1.034.356
2016 -14.789.436.333 100.01%
2017 -10.731.813.138 -37.81%
2018 6.834.394.043 257.03%
2019 4.469.008.038 -52.93%
2020 6.070.285.859 26.38%
2021 4.441.267.227 -36.68%
2022 30.871.720.889 85.61%
2023 21.855.254.830 -41.26%
2024 3.212.407.638 -580.34%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Humedix Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 11.706.215
2016 7.609.285.004 99.85%
2017 8.765.496.460 13.19%
2018 23.802.879.239 63.17%
2019 13.809.722.494 -72.36%
2020 23.762.116.518 41.88%
2021 19.184.529.552 -23.86%
2022 38.152.026.545 49.72%
2023 30.885.207.981 -23.53%
2024 7.872.861.569 -292.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Humedix Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 10.671.859
2016 22.398.721.337 99.95%
2017 19.497.309.598 -14.88%
2018 16.968.485.196 -14.9%
2019 9.340.714.456 -81.66%
2020 17.691.830.659 47.2%
2021 14.743.262.325 -20%
2022 7.280.305.656 -102.51%
2023 9.029.953.151 19.38%
2024 4.660.453.931 -93.76%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Humedix Co., Ltd. Equity
Year Equity Growth
2015 109.802.416.000
2016 113.008.083.556 2.84%
2017 113.908.655.656 0.79%
2018 113.678.299.936 -0.2%
2019 121.371.830.708 6.34%
2020 134.877.159.867 10.01%
2021 141.952.220.695 4.98%
2022 139.109.651.753 -2.04%
2023 198.063.056.238 29.76%
2024 213.329.219.230 7.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Humedix Co., Ltd. Assets
Year Assets Growth
2015 115.899.949.000
2016 131.158.761.772 11.63%
2017 129.739.260.179 -1.09%
2018 128.275.533.453 -1.14%
2019 138.421.304.730 7.33%
2020 175.646.541.389 21.19%
2021 217.996.960.763 19.43%
2022 227.136.347.059 4.02%
2023 219.977.705.859 -3.25%
2024 234.377.583.691 6.14%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Humedix Co., Ltd. Liabilities
Year Liabilities Growth
2015 5.755.032.000
2016 18.150.678.216 68.29%
2017 15.830.604.523 -14.66%
2018 14.597.233.517 -8.45%
2019 17.049.474.021 14.38%
2020 40.769.381.522 58.18%
2021 76.044.740.068 46.39%
2022 88.026.695.306 13.61%
2023 21.914.649.621 -301.68%
2024 21.048.364.461 -4.12%

Humedix Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
15752.92
Net Income per Share
3044.2
Price to Earning Ratio
10.97x
Price To Sales Ratio
2.21x
POCF Ratio
7.69
PFCF Ratio
10.97
Price to Book Ratio
1.62
EV to Sales
1.68
EV Over EBITDA
5.35
EV to Operating CashFlow
6.1
EV to FreeCashFlow
8.36
Earnings Yield
0.09
FreeCashFlow Yield
0.09
Market Cap
360,38 Bil.
Enterprise Value
274,52 Bil.
Graham Number
37529.51
Graham NetNet
9808.63

Income Statement Metrics

Net Income per Share
3044.2
Income Quality
1.43
ROE
0.16
Return On Assets
0.13
Return On Capital Employed
0.19
Net Income per EBT
0.73
EBT Per Ebit
1.08
Ebit per Revenue
0.24
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.46
Operating Profit Margin
0.24
Pretax Profit Margin
0.27
Net Profit Margin
0.19

Dividends

Dividend Yield
0.02
Dividend Yield %
1.72
Payout Ratio
0.17
Dividend Per Share
575

Operating Metrics

Operating Cashflow per Share
4341.23
Free CashFlow per Share
3165.97
Capex to Operating CashFlow
0.27
Capex to Revenue
0.07
Capex to Depreciation
1.08
Return on Invested Capital
0.15
Return on Tangible Assets
0.14
Days Sales Outstanding
58.46
Days Payables Outstanding
22.97
Days of Inventory on Hand
122.92
Receivables Turnover
6.24
Payables Turnover
15.89
Inventory Turnover
2.97
Capex per Share
1175.26

Balance Sheet

Cash per Share
8.503,77
Book Value per Share
20.563,17
Tangible Book Value per Share
20339.97
Shareholders Equity per Share
20563.17
Interest Debt per Share
525.46
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-1.67
Current Ratio
7.61
Tangible Asset Value
211,01 Bil.
Net Current Asset Value
124,18 Bil.
Invested Capital
181776677085
Working Capital
126,15 Bil.
Intangibles to Total Assets
0.01
Average Receivables
24,44 Bil.
Average Payables
6,23 Bil.
Average Inventory
28969706075.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Humedix Co., Ltd. Dividends
Year Dividends Growth
2015 286
2016 477 40.13%
2022 500 4.8%
2024 575 13.04%

Humedix Co., Ltd. Profile

About Humedix Co., Ltd.

Humedix Co., Ltd., a healthcare company, researches, develops, manufactures, and sells various pharmaceutical products in South Korea. It offers over-the-counter drugs, prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic products, and functional synthetic materials, as well as health functional foods. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. The company was founded in 2002 and is headquartered in Anyang-si, South Korea.

CEO
Jin-hwan Kim
Employee
226
Address
603, 268, Hagui-ro
Anyang-Si, 14056

Humedix Co., Ltd. Executives & BODs

Humedix Co., Ltd. Executives & BODs
# Name Age
1 Jin-hwan Kim
Chief Executive Officer
70

Humedix Co., Ltd. Competitors

Vieworks Co., Ltd. Logo
Vieworks Co., Ltd.

100120.KQ

(0.0)
InBody Co.,Ltd Logo
InBody Co.,Ltd

041830.KQ

(0.0)
Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
GeneOne Life Science, Inc. Logo
GeneOne Life Science, Inc.

011000.KS

(1.0)